This phase I trial investigates the safety of testosterone replacement therapy around the time of major urologic surgery (perioperative) in order to improve quality of life and post-operative outcomes such as decreased length of hospital stay, complications, and mortality in patients with low testosterone levels. Studies have demonstrated that patients undergoing testosterone replacement therapy have increased lean body mass, decreased fat mass and have improved physical function. Testosterone replacement therapy can also stimulate bone formation and may decrease the risk of fracture. Information from this trial may be used to support the incorporation of testosterone level testing and testosterone replacement into the perioperative treatment decision-making process.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Changes in quality of life before and after surgery
Timeframe: Baseline to 3 months
Change in frailty phenotype before and after surgery
Timeframe: Baseline, post operative refers to the period after the procedure until final follow up and study completion. Will occur an average of 90 days after the procedure.
Major complications
Timeframe: Within 90 days of surgery
Minor complications
Timeframe: Within 90 days of surgery
Rate of intensive care unit (ICU) admission
Timeframe: Up to 3 months post-surgery
Hospital length of stay
Timeframe: Up to 3 months post-operative
Discharge disposition
Timeframe: Discharge from hospital
Unplanned readmissions
Timeframe: Within 90 days of surgery
Mortality rate
Timeframe: Within 90 days of surgery
Testosterone level
Timeframe: Up to 3 months post-operative